# Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

> **NCT04470947** · — · UNKNOWN · sponsor: **Medical University of Vienna** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Lymphoma
- Refractory Lymphoma
- Refractory Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory T-Cell Lymphoma

## Interventions

- **DIAGNOSTIC_TEST:** Next generation functional drug screening
- **DIAGNOSTIC_TEST:** Comprehensive genomic profiling

## Key facts

- **NCT ID:** NCT04470947
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-10
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470947, "Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04470947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*